Medullary Thyroid Cancer - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：109頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Medullary Thyroid Cancer - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Medullary Thyroid Cancer - Pipeline Review, H1 2014’, provides an overview of the Medullary Thyroid Cancer’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Medullary Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Medullary Thyroid Cancer and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Medullary Thyroid Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Medullary Thyroid Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Medullary Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Medullary Thyroid Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Medullary Thyroid Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Medullary Thyroid Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Medullary Thyroid Cancer - Pipeline Review, H1 2014’, provides an overview of the Medullary Thyroid Cancer’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Medullary Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Medullary Thyroid Cancer and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Medullary Thyroid Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Medullary Thyroid Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Medullary Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Medullary Thyroid Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Medullary Thyroid Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Medullary Thyroid Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Medullary Thyroid Cancer Overview 7
Therapeutics Development 8
Pipeline Products for Medullary Thyroid Cancer - Overview 8
Pipeline Products for Medullary Thyroid Cancer - Comparative Analysis 9
Medullary Thyroid Cancer - Therapeutics under Development by Companies 10
Medullary Thyroid Cancer - Therapeutics under Investigation by Universities/Institutes 12
Medullary Thyroid Cancer - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Unknown Stage Products 16
Medullary Thyroid Cancer - Products under Development by Companies 17
Medullary Thyroid Cancer - Products under Investigation by Universities/Institutes 18
Medullary Thyroid Cancer - Companies Involved in Therapeutics Development 19
AstraZeneca PLC 19
Novartis AG 20
Exelixis, Inc. 21
Ariad Pharmaceuticals, Inc. 22
OXiGENE, Inc. 23
Nerviano Medical Sciences S.r.l. 24
Globeimmune, Inc. 25
Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. 26
Medullary Thyroid Cancer - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 31
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
vandetanib - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
cabozantinib (s)-malate - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
vandetanib - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
pasireotide - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
ponatinib - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
GI-6207 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Anlotinib Hydrochloride - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
CLM-29 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
NMS-616 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
RET Inhibitor - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
fosbretabulin tromethamine - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Medullary Thyroid Cancer - Recent Pipeline Updates 68
Medullary Thyroid Cancer - Dormant Projects 99
Medullary Thyroid Cancer - Product Development Milestones 100
Featured News & Press Releases 100
Dec 19, 2013: COMETRIQ Receives Positive Opinion from European Committee for Medicinal Products for Human Use for Progressive, Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma 100
Jun 02, 2013: Exelixis Presents Cometriq Clinical Trial Data In Patients With Progressive, Metastatic Medullary Thyroid Cancer 100
May 07, 2013: Exelixis To Feature Nine Presentations On Cabozantinib At 2013 ASCO Annual Meeting 102
Apr 08, 2013: Ariad Pharma Presents New Preclinical Data On Ponatinib At AACR Annual Meeting 2013 103
Apr 03, 2013: GlobeImmune Initiates Phase II Study Of New T Cell Stimulating Cancer Vaccine Targeting CEA In Patients With Metastatic Medullary Thyroid Cancer 104
Feb 14, 2013: Eisai's Thyroid Cancer Drug Candidate Lenvatinib Obtains FDA Orphan Drug Status 105
Jan 24, 2013: Exelixis’s Cometriq Is Now Available In US 105
Dec 07, 2012: Catalent Pharma To Supply FDA Approved Exelixis's Cometriq In US Market 105
Nov 29, 2012: Exelixis Announces EMA Acceptance Of Marketing Authorization Application For Thyroid Cancer Drug Cometriq 106
Nov 29, 2012: Exelixis's Cometriq Obtains FDA Approval For Treatment Of Metastatic Medullary Thyroid Cancer 106
Appendix 108
Methodology 108
Coverage 108
Secondary Research 108
Primary Research 108
Expert Panel Validation 108
Contact Us 109
Disclaimer 109
List of Tables
Number of Products under Development for Medullary Thyroid Cancer, H1 2014 8
Number of Products under Development for Medullary Thyroid Cancer - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 12
Comparative Analysis by Late Stage Development, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 14
Comparative Analysis by Early Stage Development, H1 2014 15
Comparative Analysis by Unknown Stage Development, H1 2014 16
Products under Development by Companies, H1 2014 17
Products under Investigation by Universities/Institutes, H1 2014 18
Medullary Thyroid Cancer - Pipeline by AstraZeneca PLC, H1 2014 19
Medullary Thyroid Cancer - Pipeline by Novartis AG, H1 2014 20
Medullary Thyroid Cancer - Pipeline by Exelixis, Inc., H1 2014 21
Medullary Thyroid Cancer - Pipeline by Ariad Pharmaceuticals, Inc., H1 2014 22
Medullary Thyroid Cancer - Pipeline by OXiGENE, Inc., H1 2014 23
Medullary Thyroid Cancer - Pipeline by Nerviano Medical Sciences S.r.l., H1 2014 24
Medullary Thyroid Cancer - Pipeline by Globeimmune, Inc., H1 2014 25
Medullary Thyroid Cancer - Pipeline by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd., H1 2014 26
Assessment by Monotherapy Products, H1 2014 27
Number of Products by Stage and Target, H1 2014 30
Number of Products by Stage and Mechanism of Action, H1 2014 33
Number of Products by Stage and Route of Administration, H1 2014 35
Number of Products by Stage and Molecule Type, H1 2014 37
Medullary Thyroid Cancer Therapeutics - Recent Pipeline Updates, H1 2014 68
Medullary Thyroid Cancer - Dormant Projects, H1 2014 99
List of Figures
Number of Products under Development for Medullary Thyroid Cancer, H1 2014 8
Number of Products under Development for Medullary Thyroid Cancer - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Late Stage Development, H1 2014 13
Comparative Analysis by Early Stage Products, H1 2014 15
Assessment by Monotherapy Products, H1 2014 27
Number of Products by Top 10 Target, H1 2014 28
Number of Products by Stage and Top 10 Target, H1 2014 29
Number of Products by Top 10 Mechanism of Action, H1 2014 31
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 32
Number of Products by Top 10 Route of Administration, H1 2014 34
Number of Products by Stage and Top 10 Route of Administration, H1 2014 35
Number of Products by Top 10 Molecule Type, H1 2014 36
Number of Products by Stage and Top 10 Molecule Type, H1 2014 37
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Medullary Thyroid Cancer Overview 7
Therapeutics Development 8
Pipeline Products for Medullary Thyroid Cancer - Overview 8
Pipeline Products for Medullary Thyroid Cancer - Comparative Analysis 9
Medullary Thyroid Cancer - Therapeutics under Development by Companies 10
Medullary Thyroid Cancer - Therapeutics under Investigation by Universities/Institutes 12
Medullary Thyroid Cancer - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Unknown Stage Products 16
Medullary Thyroid Cancer - Products under Development by Companies 17
Medullary Thyroid Cancer - Products under Investigation by Universities/Institutes 18
Medullary Thyroid Cancer - Companies Involved in Therapeutics Development 19
AstraZeneca PLC 19
Novartis AG 20
Exelixis, Inc. 21
Ariad Pharmaceuticals, Inc. 22
OXiGENE, Inc. 23
Nerviano Medical Sciences S.r.l. 24
Globeimmune, Inc. 25
Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. 26
Medullary Thyroid Cancer - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 31
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
vandetanib - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
cabozantinib (s)-malate - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
vandetanib - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
pasireotide - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
ponatinib - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
GI-6207 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Anlotinib Hydrochloride - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
CLM-29 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
NMS-616 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
RET Inhibitor - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
fosbretabulin tromethamine - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Medullary Thyroid Cancer - Recent Pipeline Updates 68
Medullary Thyroid Cancer - Dormant Projects 99
Medullary Thyroid Cancer - Product Development Milestones 100
Featured News & Press Releases 100
Dec 19, 2013: COMETRIQ Receives Positive Opinion from European Committee for Medicinal Products for Human Use for Progressive, Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma 100
Jun 02, 2013: Exelixis Presents Cometriq Clinical Trial Data In Patients With Progressive, Metastatic Medullary Thyroid Cancer 100
May 07, 2013: Exelixis To Feature Nine Presentations On Cabozantinib At 2013 ASCO Annual Meeting 102
Apr 08, 2013: Ariad Pharma Presents New Preclinical Data On Ponatinib At AACR Annual Meeting 2013 103
Apr 03, 2013: GlobeImmune Initiates Phase II Study Of New T Cell Stimulating Cancer Vaccine Targeting CEA In Patients With Metastatic Medullary Thyroid Cancer 104
Feb 14, 2013: Eisai's Thyroid Cancer Drug Candidate Lenvatinib Obtains FDA Orphan Drug Status 105
Jan 24, 2013: Exelixis’s Cometriq Is Now Available In US 105
Dec 07, 2012: Catalent Pharma To Supply FDA Approved Exelixis's Cometriq In US Market 105
Nov 29, 2012: Exelixis Announces EMA Acceptance Of Marketing Authorization Application For Thyroid Cancer Drug Cometriq 106
Nov 29, 2012: Exelixis's Cometriq Obtains FDA Approval For Treatment Of Metastatic Medullary Thyroid Cancer 106
Appendix 108
Methodology 108
Coverage 108
Secondary Research 108
Primary Research 108
Expert Panel Validation 108
Contact Us 109
Disclaimer 109
List of Tables
Number of Products under Development for Medullary Thyroid Cancer, H1 2014 8
Number of Products under Development for Medullary Thyroid Cancer - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 12
Comparative Analysis by Late Stage Development, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 14
Comparative Analysis by Early Stage Development, H1 2014 15
Comparative Analysis by Unknown Stage Development, H1 2014 16
Products under Development by Companies, H1 2014 17
Products under Investigation by Universities/Institutes, H1 2014 18
Medullary Thyroid Cancer - Pipeline by AstraZeneca PLC, H1 2014 19
Medullary Thyroid Cancer - Pipeline by Novartis AG, H1 2014 20
Medullary Thyroid Cancer - Pipeline by Exelixis, Inc., H1 2014 21
Medullary Thyroid Cancer - Pipeline by Ariad Pharmaceuticals, Inc., H1 2014 22
Medullary Thyroid Cancer - Pipeline by OXiGENE, Inc., H1 2014 23
Medullary Thyroid Cancer - Pipeline by Nerviano Medical Sciences S.r.l., H1 2014 24
Medullary Thyroid Cancer - Pipeline by Globeimmune, Inc., H1 2014 25
Medullary Thyroid Cancer - Pipeline by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd., H1 2014 26
Assessment by Monotherapy Products, H1 2014 27
Number of Products by Stage and Target, H1 2014 30
Number of Products by Stage and Mechanism of Action, H1 2014 33
Number of Products by Stage and Route of Administration, H1 2014 35
Number of Products by Stage and Molecule Type, H1 2014 37
Medullary Thyroid Cancer Therapeutics - Recent Pipeline Updates, H1 2014 68
Medullary Thyroid Cancer - Dormant Projects, H1 2014 99
List of Figures
Number of Products under Development for Medullary Thyroid Cancer, H1 2014 8
Number of Products under Development for Medullary Thyroid Cancer - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Late Stage Development, H1 2014 13
Comparative Analysis by Early Stage Products, H1 2014 15
Assessment by Monotherapy Products, H1 2014 27
Number of Products by Top 10 Target, H1 2014 28
Number of Products by Stage and Top 10 Target, H1 2014 29
Number of Products by Top 10 Mechanism of Action, H1 2014 31
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 32
Number of Products by Top 10 Route of Administration, H1 2014 34
Number of Products by Stage and Top 10 Route of Administration, H1 2014 35
Number of Products by Top 10 Molecule Type, H1 2014 36
Number of Products by Stage and Top 10 Molecule Type, H1 2014 37
